Novartis lashes out at India for not respecting IPR1 min read . Updated: 18 Aug 2013, 09:11 PM IST
Novartis says India needs to have fast track courts to deal with IPR disputes
New Delhi: Hitting out at India’s way of dealing with Intellectual Property Rights (IPR) issues, drug major Novartis has said India is losing investments in research and development (R&D) from multi-national companies (MNCs) to China due to lack of an ecosystem that fosters innovation.
According to the company, which lost a patent case for its cancer drug Glivec, India needs to have fast track courts to deal with IPR disputes.
“The recent cases that we have seen in the area of IPR do not in any way point to an environment that encourages innovation. A patent is granted then revoked. A patent is granted then violated. A patent is granted then a compulsory licence is issued," Novartis India vice-chairman and managing director Ranjit Shahani told PTI.
He said that China has been able to attract leading global companies to invest in R&D, while India has been unable to do so.
“What we certainly would like to see is an ecosystem that fosters innovation and fast-track courts to hear and decide cases involving IPR. China has drawn all the leading global companies to invest in R&D there while India has not. That itself should serve as food for thought," he said.
While the Supreme Court had rejected the company’s plea for a patent on cancer drug Glivec in April, last year the government invoked compulsory licence on Bayer Corporation’s cancer-treatment drug Nexavar permitting Hyderabad-based Natco Pharma to manufacture and sell the drug at a price lesser by over 30 times charged by its patent-holder.
Shahani said the government needs to have a holistic approach and look at global companies as being part of the solution.
“All stakeholders must come together to find sustainable solutions that balance the need for innovation with the need for medicines that are affordable, all within a robust intellectual property rights environment," he said.
Setting up fast-track courts to address IPR disputes would certainly be a step in the right direction, he added.
Espousing the cause of foreign capital in the Indian pharmaceutical sector, Shahani, who is also the president of Organisation of Pharmaceutical Producers of India (OPPI), said the foreign direct investment would lead to upgrading of the country’s skills in the sector.